Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta‐analysis and meta‐regression analysis
B Galling, A Roldan, K Hagi, L Rietschel… - World …, 2017 - Wiley Online Library
Antipsychotic polypharmacy in schizophrenia is much debated, since it is common and
costly with unclear evidence for its efficacy and safety. We conducted a systematic literature …
costly with unclear evidence for its efficacy and safety. We conducted a systematic literature …
Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis
B Galling, A Roldán, K Hagi, L Rietschel, F Walyzada… - World Psychiatry, 2017 - elibrary.ru
Antipsychotic polypharmacy in schizophrenia is much debated, since it is common and
costly with unclear evidence for its efficacy and safe-ty. We conducted a systematic literature …
costly with unclear evidence for its efficacy and safe-ty. We conducted a systematic literature …
Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis
B Galling, A Roldan, K Hagi, L Rietschel, F Walyzada… - 2017 - repository.um.edu.mo
Antipsychotic polypharmacy in schizophrenia is much debated, since it is common and
costly with unclear evidence for its efficacy and safety. We conducted a systematic literature …
costly with unclear evidence for its efficacy and safety. We conducted a systematic literature …
Antipsychotic augmentation vs. monotherapy in schizophrenia: Systematic review, meta‐analysis and meta‐regression analysis.
B Galling, A Roldán, K Hagi, L Rietschel… - World …, 2017 - psycnet.apa.org
Antipsychotic polypharmacy in schizophrenia is much debated, since it is common and
costly with unclear evidence for its efficacy and safety. We conducted a systematic literature …
costly with unclear evidence for its efficacy and safety. We conducted a systematic literature …
Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis
B Galling, A Roldán, K Hagi… - … : official journal of …, 2017 - pubmed.ncbi.nlm.nih.gov
Antipsychotic polypharmacy in schizophrenia is much debated, since it is common and
costly with unclear evidence for its efficacy and safety. We conducted a systematic literature …
costly with unclear evidence for its efficacy and safety. We conducted a systematic literature …
Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis
B Galling, A Roldán, K Hagi, L Rietschel, F Walyzada… - World …, 2017 - vbn.aau.dk
Antipsychotic polypharmacy in schizophrenia is much debated, since it is common and
costly with unclear evidence for its efficacy and safety. We conducted a systematic literature …
costly with unclear evidence for its efficacy and safety. We conducted a systematic literature …
[引用][C] Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis
B Galling, A Roldán, K Hagi, L Rietschel, F Walyzada… - World …, 2017 - cir.nii.ac.jp
Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis
and meta-regression analysis | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …
and meta-regression analysis | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …
Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis.
B Galling, A Roldán, K Hagi, L Rietschel, F Walyzada… - 2017 - mediatum.ub.tum.de
Antipsychotic polypharmacy in schizophrenia is much debated, since it is common and
costly with unclear evidence for its efficacy and safety. We conducted a systematic literature …
costly with unclear evidence for its efficacy and safety. We conducted a systematic literature …
Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis.
B Galling, A Roldán, K Hagi, L Rietschel… - World psychiatry: official …, 2017 - sonar.ch
English Antipsychotic polypharmacy in schizophrenia is much debated, since it is common
and costly with unclear evidence for its efficacy and safety. We conducted a systematic …
and costly with unclear evidence for its efficacy and safety. We conducted a systematic …
[引用][C] Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis
B Galling, A Roldán, K Hagi, L Rietschel… - World …, 2017 - boris.unibe.ch
BORIS Deutsch English Français Login BORIS Bern Open Repository and Information
System University of Bern Home Statistics Antipsychotic augmentation vs. monotherapy in …
System University of Bern Home Statistics Antipsychotic augmentation vs. monotherapy in …